Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antisense-Therapie aktiviert Triglyzeridabbau

Chylomikronämie-Syndrom innovativ therapiert

  • 6 Accesses

This is a preview of subscription content, log in to check access.

Abb. 1

© Kai Toussaint

Literatur

  1. 1.

    Stroes E et al. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1-7

  2. 2.

    Gaudet D et al. Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. J Clin Lipidol. 2016;10:680-1

  3. 3.

    Davidson M et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018;12:898-907

  4. 4.

    Moulin P et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018;275:265-72

  5. 5.

    Ueda M et al. A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyzeridemia and Pancreatitis. J Clin Endocrinol Metab. 2017;102:1454-7

  6. 6.

    Witztum JL et al. Volanesorsen and triglyzeride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531-42

Download references

Author information

Correspondence to Kai Toussaint.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Toussaint, K. Chylomikronämie-Syndrom innovativ therapiert. CV 20, 24–25 (2020). https://doi.org/10.1007/s15027-019-0412-0

Download citation